Source - RNS
RNS Number : 8291K
C4X Discovery Holdings PLC
26 September 2016


This announcement contains inside information


C4X Discovery Holdings plc

("C4XD" or the "Company")


Result of General Meeting


C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery and development company, today announces that at the General Meeting held earlier today, all the resolutions put to shareholders were duly passed.

As a result, the placing announced on 6 September 2016 of 4,901,961 new ordinary shares at 102 pence per ordinary share to raise £5.0 million, is conditional only on Admission which is expected to take place on 27 September 2016.

Following Admission, the Company's issued share capital will consist of 37,398,718 ordinary shares. There are no ordinary shares held in treasury. Therefore, in accordance with the FCA's Disclosure and Transparency Rule 5.6.1, the Company confirms that following Admission, the total number of voting rights in the Company will be 37,398,718.




For further information please contact:

C4X Discovery Holdings plc

Clive Dix, Chief Executive Officer                                                                                            07801 865803


Zeus Capital Limited

Dan Bate/Phil Walker                                                                                                                    0161 831 1512

Dominic Wilson                                                                                                                                0203 829 5000


Consilium Strategic Communications

Mary-Jane Elliott, Chris Gardner, Matthew Neal, Melissa Gardiner                          0203 709 5700 



About C4X Discovery

C4X Discovery aims to become the world's most productive drug discovery and development company by exploiting cutting-edge technologies to design and create best-in-class drug candidates. The Company has two proprietary and synergistic software platforms "Taxonomy3®" and "Conformetrix" that provide a significant competitive advantage when combined with an experienced management team. "Taxonomy3®" is a human genetics analysis platform that utilises a unique mathematical approach to discovery and validation of drug targets for the treatment of a variety of diseases. "Conformetrix" determines the 3D shape of drug molecules from experimental in vitro data that enables the rapid design and discovery of novel and potent drugs for diseases with high unmet medical need across broad therapeutic areas. We have a hybrid business model of wholly-owned programmes and partnerships with pharma, biotech and academics.


The Company was founded in 2008 as a spin-out from the University of Manchester and has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically. For additional information please go to:



This information is provided by RNS
The company news service from the London Stock Exchange